Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1729-1736

  Hamadani, Mehdi ^a   Hari, Parameswaran N ^a   Zhang, Ying ^a   Carreras, Jeanette ^a   Akpek, Görgün ^b   Aljurf, Mahmoud D ^c   Ayala, Ernesto ^d   Bachanova, Veronika ^e   Chen, Andy I ^f   Chen, Yi Bin ^g   Costa, Luciano J ^h   Fenske, Timothy S ^a   Freytes, César O ⁱ   Ganguly, Siddhartha ^j   Hertzberg, Mark S ^k   Holmberg, Leona A ^l   Inwards, David J ^m   Kamble, Rammurti T ⁿ   Kanfer, Edward J ^o   Lazarus, Hillard M ^p   Marks, David I ^q   Nishihori, Taiga ^d   Olsson, Richard ^r,s   Reddy, Nishitha M ^t   Rizzieri, David A ^u   Savani, Bipin N ^t   Solh, Melhem ^x   Vose, Julie M ^v   Wirk, Baldeep ^w   Maloney, David G ^v   Smith, Sonali M ^x   Montoto, Silvia ^y   Saber, Wael ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Banner MD Anderson Cancer Center   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j BMT Program Saint Luke's Blood and Marrow Transplant Program   (United States)

^k WESTMEAD HOSPITAL   (Australia)

^l Fred Hutchinson Cancer Research Center   (United States)

^m MAYO CLINIC   (United States)

ⁿ CENTER FOR CELL AND GENE THERAPY   (United States)

^o HAMMERSMITH HOSPITAL   (United Kingdom)

^p UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^q UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^r KAROLINSKA INSTITUTE   (Sweden)

^s UPPSALA UNIVERSITY   (Sweden)

^t VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^u DUKE UNIVERSITY   (United States)

^v NEBRASKA MEDICAL CENTER   (United States)

^w STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^x UNIVERSITY OF CHICAGO   (United States)

^y ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

more..

Author keywords

Aggressive lymphoma; Autologous transplantation; Diffuse large Bcell lymphoma; Early failure; High dose therapy; Non Hodgkin lymphoma; Rituximab

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; ADVERSE EFFECTS; AGED; AUTOTRANSPLANTATION; COHORT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908019168     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.036     Document Type: Article

References (35)

1. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. NEngl J Med 1987, 316:1493-1498.
2. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. NEngl J Med 1995, 333:1540-1545.
3. Verdonck L.F., van Putten W.L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. NEngl J Med 1995, 332:1045-1051.
4. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEngl J Med 2002, 346:235-242.
5. Coiffier B., Thieblemont C., Van Den Neste E., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
6. Pfreundschuh M., Kuhnt E., Trumper L., et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011, 12:1013-1022.
7. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
8. Gisselbrecht C. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?. Hematology Am Soc Hematol Educ Program 2012, 2012:410-416.
9. Vose J.M., Zhang M.J., Rowlings P.A., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. JClin Oncol 2001, 19:406-413.
10. Gascoyne R.D., Moskowitz C., Shea T.C. Controversies in BMT for lymphoma. Biol Blood Marrow Transplant 2013, 19:S26-32.
11. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JClin Oncol 2010, 28:4184-4190.
12. Clark T.G., Altman D.G., De Stavola B.L. Quantification of the completeness of follow-up. Lancet 2002, 359:1309-1310.
13. Fenske T.S., Hari P.N., Carreras J., et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009, 15:1455-1464.
14. Lazarus H.M., Zhang M.J., Carreras J., et al. Acomparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010, 16:35-45.
15. Mounier N., Canals C., Gisselbrecht C., et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012, 18:788-793.
16. Guglielmi C., Gomez F., Philip T., et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. JClin Oncol 1998, 16:3264-3269.
17. Martin A., Conde E., Arnan M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
18. Matasar M.J., Czuczman M.S., Rodriguez M.A., et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 2013, 122:499-506.
19. Fayad L., Offner F., Smith M.R., et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. JClin Oncol 2013, 31:573-583.
20. Thieblemont C., Briere J., Mounier N., et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. JClin Oncol 2011, 29:4079-4087.
21. Vose J.M., Carter S., Burns L.J., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. JClin Oncol 2013, 31:1662-1668.
22. Gisselbrecht C., Schmitz N., Mounier N., et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. JClin Oncol 2012, 30:4462-4469.
23. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. JClin Oncol 2013, 31:4199-4206.
24. Yang Y., Shaffer A.L., Emre N.C., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
25. Mathews Griner L.A., Guha R., Shinn P., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U.S.A 2014, 111:2349-2354.
26. Glass B., Hasenkamp J., Wulf G., et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014, 15:757-766.
27. Bacher U., Klyuchnikov E., Le-Rademacher J., et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. Blood 2012, 120:4256-4262.
28. Hamadani M., Saber W., Ahn K.W., et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013, 19:746-753.
29. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
30. Savage K.J., Johnson N.A., Ben-Neriah S., et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
31. Cuccuini W., Briere J., Mounier N., et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012, 119:4619-4624.
32. Moskowitz C.H., Zelenetz A.D., Kewalramani T., et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005, 106:3383-3385.
33. Costa L.J., Feldman A.L., Micallef I.N., et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008, 142:404-412.
34. Gu K., Weisenburger D.D., Fu K., et al. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematol Oncol 2012, 30:143-149.
35. Armand P., Welch S., Kim H.T., et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013, 160:608-617.